Previous 10 | Next 10 |
Recently completed financing provides sufficient funds for near-term Parkinson’s Disease priority Plans for Phase 2b trial of NE3107 as first-line monotherapy for Parkinson’s Disease being finalized with targeted launch late-summer 2024 Once-daily NE3107 formulatio...
CARSON CITY, Nev., March 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-dege...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 61.6% to $0.143 on volume of 387,468,585 shares Fisker Inc. Class A (FSR) fell 8.5% to $0.4415 on volume of 205,557,321 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 3.0% to $3.22 on vol...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 58.0% to $0.1398 on volume of 323,150,710 shares Fisker Inc. Class A (FSR) fell 6.7% to $0.45 on volume of 175,737,100 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 6.2% to $3.115 on vol...
A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 33.7% to $0.4825 on volume of 369,944,141 shares Jaguar Health Inc. (JAGX) rose 50.0% to $0.0885 on volume of 303,339,477 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 12.6% to $3.32 on ...
CARSON CITY, Nev., March 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-dege...
2024-03-02 06:18:00 ET 3 Top Habits for Penny Stocks Traders to Follow in 2024 Trading penny stocks presents unique opportunities for investors looking for significant returns on investment. Despite the volatility associated with these low-priced shares, successful traders adhere to spe...
CARSON CITY, Nev., March 01, 2024 (GLOBE NEWSWIRE) -- Carson City, Nevada – March 1, 2024 – BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disea...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 44.2% to $0.0851 on volume of 271,253,038 shares Fisker Inc. Class A (FSR) fell 27.2% to $0.53 on volume of 253,915,529 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 12.5% to $3.325 on v...
SAN FRANCISCO, CA / ACCESSWIRE / March 1, 2024 / Hagens Berman urges BioVie Inc. (NASDAQ:BIVI) investors who suffered substantial losses to submit your losses now . Class Period: Aug. 5, 2021 - Nov. 29, 2023 Lead Plaintiff Deadline: Mar. 19, 2024 Visit: www.hbsslaw.com/investor-frau...
News, Short Squeeze, Breakout and More Instantly...
BioVie Inc. Company Name:
BIVI Stock Symbol:
OTCMKTS Market:
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...
Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID Bezisterim, an anti-inflammatory and insulin-sensitizer that permeates the blood brain barrier, could represent a novel oral treatment targeting a...